chr17-35100954-C-A
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PM4
The NM_002878.4(RAD51D):c.986G>T(p.Ter329LeuextTer56) variant causes a stop lost change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. *329*) has been classified as Likely benign.
Frequency
Consequence
NM_002878.4 stop_lost
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
RAD51D | NM_002878.4 | c.986G>T | p.Ter329LeuextTer56 | stop_lost | 10/10 | ENST00000345365.11 | |
RAD51L3-RFFL | NR_037714.1 | n.655+247G>T | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
RAD51D | ENST00000345365.11 | c.986G>T | p.Ter329LeuextTer56 | stop_lost | 10/10 | 1 | NM_002878.4 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 31, 2023 | The c.986G>T variant (also known as p.*329LEXT*56), located in coding exon 10 of the RAD51D gene, results from a G to T substitution at nucleotide position 986, which is the last nucleotide of the RAD51D gene. The stop codon at position 329 is replaced by Leucine, resulting in an elongation of the protein by 56 amino acids. The exact functional impact of these added amino acids is unknown at this time. This nucleotide position is well conserved in available vertebrate species. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Breast-ovarian cancer, familial, susceptibility to, 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 18, 2021 | This variant is not present in population databases (ExAC no frequency). This sequence change disrupts the translational stop signal of the RAD51D mRNA. It is expected to extend the length of the RAD51D protein by 56 additional amino acid residues. This variant has not been reported in the literature in individuals with RAD51D-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at